Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

1081. The costs and outcomes of multifaceted interventions designed to improve the care of congestive heart failure in the inpatient setting: a review of the literature

The costs and outcomes of multifaceted interventions designed to improve the care of congestive heart failure in the inpatient setting: a review of the literature The costs and outcomes of multifaceted interventions designed to improve the care of congestive heart failure in the inpatient setting: a review of the literature The costs and outcomes of multifaceted interventions designed to improve the care of congestive heart failure in the inpatient setting: a review of the literature Balinsky W (...) for people with heart failure. Searching MEDLINE was searched from 1988 to 2000 for English language studies; the search terms were provided. The 'Related Articles' function of PubMed was also used and bibliographies of relevant papers were checked. Study selection Study designs of evaluations included in the review The authors were primarily interested in randomised controlled trials (RCTs) but they also looked for pre-intervention post-intervention studies for a secondary analysis. Specific

DARE.2003

1082. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials

Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials Pittler M H, Schmidt K, Ernst E CRD summary This well-conducted review assessed the use of hawthorn extract to treat patients with chronic heart failure. The authors concluded that hawthorn extract has significant benefits, compared (...) with placebo, as an adjunctive treatment for patients with chronic heart failure. The conclusions are reliable Authors' objectives To assess the efficacy of adjunctive treatment with hawthorn extract for patients with chronic heart failure (CHF). Searching MEDLINE, EMBASE, the Cochrane Library, CINAHL, CISCOM and AMED were each searched from inception to June 2002; the search terms were stated. Ten manufacturers of commercial hawthorn preparations and nine experts in the field were contacted for additional

DARE.2003

1083. Care management interventions for older patients with congestive heart failure

Care management interventions for older patients with congestive heart failure Care management interventions for older patients with congestive heart failure Care management interventions for older patients with congestive heart failure Windham B G, Bennett R G, Gottlieb S CRD summary This review aimed to assess the effectiveness of care management programmes for older people with heart failure. The authors concluded that such programmes can be effective and elements of effective programmes (...) include mixed teams, frequent monitoring and patient education. The review had a number of methodological and reporting weaknesses and hence the conclusions may not be reliable. Authors' objectives The authors aimed to identify interventions for inclusion in care management programmes for older people with congestive heart failure (CHF), and to assess the overall effects of these programmes. Searching MEDLINE (from 1966 to March 2002) was searched for English language papers. The reference lists

DARE.2003

1084. Beta-blocker benefit according to severity of heart failure

Beta-blocker benefit according to severity of heart failure Beta-blocker benefit according to severity of heart failure Beta-blocker benefit according to severity of heart failure Bouzamondo A, Hulot J S, Sanchez P, Lechat P CRD summary This review concluded that the degree of benefit from treatment with beta-blockers is similar regardless of the severity of heart failure (except for severe end-stage heart failure). The conclusions appear to follow from the evidence presented (...) , but it is difficult to comment on the reliability of the conclusions because of lack of detail about the review methods and included studies. Authors' objectives To examine the relationship between the amplitude of benefit of beta-blockers and severity of disease in chronic heart failure. Searching MEDLINE was searched, but the dates of the searches and the search terms used were not provided. Trials from previous meta-analyses of beta-blockers for heart failure were also included. The authors of identified

DARE.2003

1085. B-type natriuretic peptide: a review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians

B-type natriuretic peptide: a review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians B-type natriuretic peptide: a review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians B-type natriuretic peptide: a review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians Cardarelli R, Lumicao T G CRD summary This review aimed (...) to assess the value of B-type natriuretic peptide (BNP) measurements for managing patients with congestive heart failure. The authors concluded that BNP determinations are useful in a limited number of clinical scenarios. However, since the review was poorly reported and suffered from methodological weaknesses, the conclusions should be interpreted with caution. Authors' objectives To assess the potential value of B-type natriuretic peptide (BNP) measurements for managing patients with congestive heart failure

DARE.2003

1086. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial

Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial Cleland (...) J G F, Takala A, Apajasalo M, Zethraeus N, Kobelt G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Patients with severe low-output heart failure in hospital, were given levosimendan, an intravenous calcium sensitiser

NHS Economic Evaluation Database.2003

1087. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure

Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure de Lissovoy G, Stier D M, Ciesla G, Munger M, Burger A J Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of nesiritide (0.015 microg/kg per minute) for patients emergently hospitalised with symptomatic decompensated heart failure (HF). Type of intervention Treatment. Economic study type Cost-effectiveness analysis

NHS Economic Evaluation Database.2003

1088. Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care?

Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care? Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care? Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care? Ledwidge M, Barry M, Cahill J, Ryan E, Maurer B, Ryder M, Travers B, Timmons L, McDonald K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) understanding, and salt restriction. Support comprised nurse-led care on three or more occasions through telephone contact and outpatient clinic visits. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised individuals presenting at casualty with a diagnosis of HF. The patients were at least 18 years of age. Patients presenting with HF in the setting of myocardial infarction or unstable angina, or in whom HF was not

NHS Economic Evaluation Database.2003

1089. Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure

Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure Lewis D A, Gurram N R, Abraham W T, Akers W S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Nesiritide was compared with milrinone in the treatment of acute decompensated heart failure (ADHF). Nesiritide was administered as an intravenous (IV) bolus of 2 microg/kg followed by a fixed dose by IV infusion of 0.01 microg/kg per minute. Milrinone was administered as an IV infusion at an average rate of 0.4 microg/kg per minute. Type of intervention

NHS Economic Evaluation Database.2003

1090. Cost-effectiveness for the management of chronic heart failure: cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan

Cost-effectiveness for the management of chronic heart failure: cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan Cost-effectiveness for the management of chronic heart failure: cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan Cost-effectiveness for the management of chronic heart failure: cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan Inomata T Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of beta-blockers (carvedilol in particular) for chronic heart failure (CHF). The doses in the present study were not specified, but doses of 5 and 20 mg/day were mentioned from the literature. Type

NHS Economic Evaluation Database.2003

1091. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era

Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide (...) heart failure, CHF), developing during the course of doxorubicin (DOX) therapy, a commonly used chemotherapeutic agent in cancer patients, was examined. The diagnostic approach used for LVEF monitoring was equilibrium radionuclide angiocardiography (ERNA). Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients diagnosed with cancer who were receiving DOX-containing chemotherapy. Setting The setting was a hospital

NHS Economic Evaluation Database.2003

1092. Cost-effectiveness of spironolactone in patients with severe heart failure

Cost-effectiveness of spironolactone in patients with severe heart failure Cost-effectiveness of spironolactone in patients with severe heart failure Cost-effectiveness of spironolactone in patients with severe heart failure Tilson L, McGowan B, Ryan M, Barry M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology The use of spironolactone (mean daily dose 25 mg) in combination with standard therapy was investigated in patients with severe heart failure. Standard therapy could include a loop diuretic, an angiotensin-converting enzyme inhibitor, digoxin, a beta-blocker, or a combination of these. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised

NHS Economic Evaluation Database.2003

1093. High-versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial

High-versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial High-versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial High-versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure (...) with heart failure, classified by the New York Heart Association (NYHA) as falling into Classes II - IV and who had a left ventricular ejection fraction (LVEF) of less than or equal to 30%, were given high-dose (32.5 - 35.0 mg/day) lisinopril therapy. These patients were compared with similar patients receiving low-dose (2.5 - 5.0 mg/day) lisinopril therapy. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised heart failure

NHS Economic Evaluation Database.2003

1094. Chronic heart failure: management of chronic heart failure in adults in primary and secondary care

Chronic heart failure: management of chronic heart failure in adults in primary and secondary care Chronic heart failure: management of chronic heart failure in adults in primary and secondary care Chronic heart failure: management of chronic heart failure in adults in primary and secondary care National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation National Institute for Clinical Excellence. Chronic heart failure: management of chronic heart failure in adults in primary and secondary care. London: National Institute for Clinical Excellence (NICE) 2003: 40 Authors' objectives This guideline offers best practice advice on the care of adult patients (aged 18 years or older) who have symptoms or a diagnosis of chronic heart failure. It aims to define the most effective combination of symptoms, signs and investigations

Health Technology Assessment (HTA) Database.2003

1095. Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness

Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness Shekelle P, Rich M, Morton S (...) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shekelle P, Rich M, Morton S. Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 82

Health Technology Assessment (HTA) Database.2003

1097. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. 12853193 2003 07 10 2003 07 23 2016 08 03 1474-547X 362 9377 2003 Jul 05 Lancet (London, England) Lancet Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. 7-13 Beta (...) blockers reduce mortality in patients who have chronic heart failure, systolic dysfunction, and are on background treatment with diuretics and angiotensin-converting enzyme inhibitors. We aimed to compare the effects of carvedilol and metoprolol on clinical outcome. In a multicentre, double-blind, and randomised parallel group trial, we assigned 1511 patients with chronic heart failure to treatment with carvedilol (target dose 25 mg twice daily) and 1518 to metoprolol (metoprolol tartrate, target dose 50 mg

Lancet2003

1098. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial.

Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. 12853194 2003 07 10 2003 07 23 2015 06 16 1474-547X 362 9377 2003 Jul 05 Lancet (London, England) Lancet Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. 14-21 The improvement in left-ventricular ejection fraction (...) (LVEF) in response to beta blockers is heterogeneous in patients with heart failure due to ischaemic heart disease, possibly indicating variations in the myocardial substrate underlying left-ventricular dysfunction. We investigated whether improvement in LVEF was associated with the volume of hibernating myocardium (viable myocardium with contractile failure). We did a double-blind, randomised trial to compare placebo and carvedilol for 6 months in individuals with stable, chronic heart failure due

Lancet2003

1099. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial.

Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. 12771115 2003 05 28 2003 06 12 2016 10 17 0098-7484 289 20 2003 May 28 JAMA JAMA Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. 2685-94 Cardiac resynchronization therapy (CRT) through biventricular pacing is an effective treatment for heart failure (HF) with a wide QRS (...) ; however, the outcomes of patients requiring CRT and implantable cardioverter defibrillator (ICD) therapy are unknown. To examine the efficacy and safety of combined CRT and ICD therapy in patients with New York Heart Association (NYHA) class III or IV congestive HF despite appropriate medical management. Randomized, double-blind, parallel-controlled trial conducted from October 1, 1999, to August 31, 2001, of 369 patients with left ventricular ejection fraction of 35% or less, QRS duration of 130 ms

JAMA2003

1100. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.

Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. 12585949 2003 02 14 2003 02 25 2016 10 17 0098-7484 289 6 2003 Feb 12 JAMA JAMA Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. 712-8 Beta-blockers remain underused despite their established utility for improving outcome in heart failure. Concerns that initiation of treatment produces few immediate benefits and may (...) have important risks may be deterring widespread use. To evaluate the early effects of the beta-blocker carvedilol in patients with severe heart failure. Randomized, double-blind, placebo-controlled trial conducted from October 28, 1997, to March 20, 2000, at 334 hospital centers in 21 countries among 2289 patients with symptoms of heart failure at rest or with minimal exertion who were clinically euvolemic and had a left ventricular ejection fraction of less than 25%. Patients were randomly

JAMA2003